RxDoctor Payments Data

Ralph Aiken

Family · Johnstown, PANPI 1053502021

Payments from drug & device makers

$8,707in general payments, 2019–2025

Across 578 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$1K
  • Lilly USA, LLC$603
  • Novo Nordisk$557
  • AstraZeneca$515
  • Boston Scientific$378
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$1922%
  • Food & beverage$8,49598%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,707 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$103,182
JardianceEmpagliflozin39$35,735
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$35,618
TrulicityDulaglutide22$24,320
OzempicSemaglutide21$21,079
XareltoRivaroxaban26$19,543
JanumetSitagliptin Phos/Metformin Hcl20$18,939
EntrestoSacubitril/Valsartan18$18,378
TradjentaLinagliptin26$17,809
Breo ElliptaFluticasone/Vilanterol37$17,790
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,780
MyrbetriqMirabegron14$9,956
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,344
Atorvastatin Calcium418$7,266
Mirabegron ErMirabegron15$6,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,067$103,182124 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$300$64,627113 claims
Boehringer IngelheimJardiance, Tradjenta$85$53,54465 claims
Lilly USA, LLCTrulicity$603$24,32022 claims
Novo NordiskOzempic$557$21,07921 claims
Johnson & JohnsonXarelto$85$19,54326 claims
MerckJanumet$150$18,93920 claims
NovartisEntresto$71$18,37818 claims
AstraZenecaBreztri Aerosphere$515$10,78017 claims
Astellas Pharma US IncMyrbetriq$103$9,95614 claims
AbbVieSynthroid$2,502$1,68736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →